Filing status
- Accounts due
- 31 December 2026
- Last accounts
- 31 March 2025
- Conf. stmt due
- 18 June 2027
- Last conf. stmt
- 4 June 2026
Cytocell Limited
- Incorporated
- 8 June 2001 (25 years)
- Previously known as
- Cytocell Technologies Limited (until 28 June 2007)Labintel Limited (until 1 March 2005)Laboratory Impex Research Limited (until 17 August 2004)
- Industry
- Other human health activities (86900)
- Directors
- Shinichi SatoKenji Iwakabe
- Accounts type
- Full
- Region
- East of England
- Address
- Oxford Gene Technology 418 Cambridge Science ParkMilton RoadCambridgeCB4 0PZ
Charges
- Total
- 2
- Outstanding
- 0
- Part satisfied
- 0
- Satisfied
- 2
Officers 5 active
Officer details are public data from the Companies House register.
Sato, Shinichi
Director · Appointed 30 April 2026
Japanese
Born April 1968 (58)
Iwakabe, Kenji
Director · Appointed 7 May 2025
Japanese
Born June 1975 (51)
Director · Appointed 28 April 2022
British
Born August 1971 (55)
Director · Appointed 30 January 2019
British
Born October 1980 (46)
Lenhardt, Anthony John
Secretary · Appointed 25 February 2016
Officer history (29 former)
30 April 2026
Appointed Sato, Shinichi as Director
30 April 2026
Resigned Oxlade, David as Director
31 March 2026
Resigned Matsuo, Naohiko as Director
25 September 2025
7 May 2025
Appointed Iwakabe, Kenji as Director
27 March 2025
Resigned Ono, Takashi as Director
27 March 2025
27 March 2025
Appointed Matsuo, Naohiko as Director
16 May 2024
Appointed Ono, Takashi as Director
28 March 2024
Resigned Kubota, Mamoru as Director
29 March 2023
Appointed Kubota, Mamoru as Director
29 March 2023
31 October 2022
Resigned Owen, David Andrew Arlwydd, Dr as Director
28 April 2022
28 April 2022
31 March 2022
30 January 2019
19 October 2018
23 February 2018
18 October 2017
17 July 2017
21 June 2017
31 May 2016
Resigned Lawrie, Neil Martin, Dr as Director
29 February 2016
Resigned Kennedy, Stewart Montgomery as Director
25 February 2016
Appointed Lenhardt, Anthony John as Secretary
25 February 2016
Appointed Owen, David Andrew Arlwydd, Dr as Director
25 February 2016
25 February 2016
Appointed Oxlade, David as Director
25 February 2016
28 February 2014
28 February 2014
28 February 2014
28 February 2014
Resigned Dart Engineering (Overseas) Ltd as Corporate Director
19 July 2012
Resigned Dreadnought Ltd as Corporate Director
19 July 2012
28 February 2012
Appointed Kennedy, Stewart Montgomery as Director
29 July 2009
21 February 2009
12 December 2008
Appointed Dreadnought Ltd as Corporate Director
11 December 2008
14 December 2006
14 December 2006
14 December 2006
14 December 2006
13 December 2006
2 March 2006
Appointed Dart Engineering (Overseas) Ltd as Corporate Director
2 March 2006
16 December 2005
27 June 2005
27 June 2005
28 February 2005
25 February 2005
25 February 2005
Appointed Lawrie, Neil Martin, Dr as Director
24 February 2005
22 February 2005
25 April 2003
27 January 2003
12 June 2001
12 June 2001
8 June 2001
8 June 2001
8 June 2001
8 June 2001
Ownership 1 active
People and entities with significant control, from the Companies House PSC register
Corporate entity · Notified 6 April 2016
Owns 75–100% of shares
Holds 75–100% of voting rights
Right to appoint and remove directors
Limited By Shares
Reg. no. 03845467
Group structure 5 companies
Ownership group derived from the Companies House PSC register
Cytocell Limited This company Owns 75–100% of shares
Oxford Gene Technology (Operations) Ltd Owns 75–100% of shares
Oxford Gene Technology (Southern) Limited Owns 75–100% of shares
Oxford Gene Technology Limited Owns 75–100% of shares
Financials
Balance sheet as at 31 March 2025 · full accounts
- Net Assets
- £38,366,393
- Cash
- £663,559
- Turnover
- £15,486,458
- Profit Before Tax
- £3,594,416
- Employees
- 76
- Debt Ratio
- 46%
- Current Ratio
- 2.3x
- Profit Margin
- 23%
- Return on Equity
- 9%
Trend
Turnover
Balance sheet detail
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Fixed Assets | £5,291,189 | £5,890,371 | £6,552,933 |
| Current Assets | £66,254,962 | £57,369,100 | £50,713,606 |
| Cash | £663,559 | £895,956 | £1,510,175 |
| Creditors (< 1 year) | £28,883,998 | £23,262,460 | £19,525,002 |
| Creditors (> 1 year) | £3,922,299 | £4,689,342 | £5,256,538 |
| Net Current Assets | £37,370,964 | £34,106,640 | £31,188,604 |
| Net Assets | £38,366,393 | £34,936,186 | £32,159,662 |
| Shareholder Funds | £38,366,393 | £34,936,186 | £32,159,662 |
| Turnover | £15,486,458 | £13,308,994 | £13,388,693 |
| Cost of Sales | £5,423,648 | £4,779,795 | £4,297,708 |
| Gross Profit | £10,062,810 | £8,529,199 | £9,090,985 |
| Admin Expenses | £6,091,780 | £5,157,503 | £4,036,130 |
| Staff Costs | £4,472,426 | £4,130,095 | £3,600,003 |
| Operating Profit | £3,846,360 | £2,923,463 | £4,457,660 |
| Profit Before Tax | £3,594,416 | £2,640,698 | £4,146,356 |
| Tax | £164,209 | (£135,826) | £636,909 |
| Profit for Period | £3,430,207 | £2,776,524 | £3,509,447 |
Filings
Recent filings only. See the full history on Companies House
| Date | Description | Made Up To | Pages | |
|---|---|---|---|---|
| 18 June 2026 | Change of details for a person with significant control | 2 | ||
| 4 June 2026 | Appointment of a director | 2 | ||
| 4 June 2026 | Confirmation statement with no updates | 4 June 2026 | 3 | |
| 4 June 2026 | Change of details for a person with significant control | 2 | ||
| 30 April 2026 | Termination of appointment of a director | 1 |
Other companies in this industry
London
Westcliff-On-Sea
Leicester
London
Newcastle Upon Tyne
London
By trade and location
Explore the largest companies
Need accounts figures, ownership or websites for thousands of companies? Bulk data & API →